Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease;Impacto de los síntomas motores y no motores en los costes directos de la enfermedad de Parkinson

Neurologia

Volumn 24, Issue 1, 2009, Pages 15-23

  Cubo, E ^a,b,d   Martin, P Martinez ^a,d   Gonzalez, M ^c,d   Frades, B ^a,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d Av Del Cid 96 ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA;

ADULT; AGED; ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; PAIN; PARKINSON DISEASE; PILOT STUDY; PSYCHOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SPAIN;

AGED; AGED, 80 AND OVER; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PILOT PROJECTS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 63449087226     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kie- burtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2 0 07;68:384-6.
2. Calabrese VP. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2 0 07;69:223-4.
3. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov Disord 2000;15:216-23.
4. Carter JH, Stewart BJ, Archbold PG, Inoue I, Jaglin J, Lannon M, et al. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov Disord 1998;13:20-8.
5. Dodel RC, Singer M, Kohne-Volland R, Szucs T, Rathay B, Scholz E, et al. The economic impact of Parkinson's disease. Pharmacoeconomics 1998;14:299-312.
6. Eisenberg JM. Clinical economics. A guide to economic analysis of clinical practices. JAMA 1989;24:2879-86.
7. Keränen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9:163-8.
8. Janca A. Parkinson's disease from WHO perspective and a public health point of view. Parkinsonism Relat Disord 2002;9:3-6.
9. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Burden of parkinsonism: a population-based study. Mov Disord 2003;18:313-6.
10. Schenkman M, Zhu CW, Cutson TM, Whetten-Goldstein K. Longitudinal evaluation of economic and physical impact of Parkinson's disease. Parkinsonism Relat Disord 2001;8:41-50.
11. Lindgren P, S. von Campenhausen, Spottke EA, Siebert U, Dodel R. Cost of Parkinson's disease in Europe. Eur J Neurol 2005;12:68-73.
12. Findley L, Aujla M, Baker M, Beech C, Browman C, Holmes J, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003;18:1139-89.
13. Welsh M. Parkinson's disease and quality of life: issues and challenges beyond motor symptoms. Neurol Clin 2004;22(Suppl. 3):S141-8.
14. Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep 2005;5:275-83.
15. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self- completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-23.
16. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
18. Ragothaman M, Govindappa ST, Rattihalli R, Subbakrishna DK, Muthane UB. Direct costs of managing Parkinson's disease in India: concerns in a developing country. Mov Disord 2006;21: 1755-8.
19. Martínez-Martín P, Forjaz MJ, Cubo E, Frades B, de Pedro Cuesta J. Global versus factor-related impression of severity in Parkinson's disease: a new clinimetric index (CISI-PD). Mov Disord 2006;21:208-14.
20. Schrag A, Selai C, Jahanshahi M, Quinn NP. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:67-73.
21. Martínez-Martín P, Benito-León J, Burguera JA, Castro A, Linazasoro G, Martínez-Castrillo JC, et al. The SCOPA-Motor Scale for assessment of Parkinson's disease is a consistent and valid measure. J Clin Epidemiol 2005;58:674-9.
22. Friedberg G, Zoldan J, Weizman A, Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 1998;21:280-4.
23. Folstein MF, Folstein Se, McHugh PR. Mini-Mental State: a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
24. Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM, et al. Assessment of cognition in Parkinson's disease. Neurology 2003;61:1222-8.
25. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of auto- nomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004;19:1306-12.
26. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neuro surg Psychiatry 2002;73:629-35.
27. Marinus J, Visser M, Martínez-Martín P, van Hilten JJ, Stiggelbout AM. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol 2003;56: 61-7.
28. Marinus J, Leentjens AF, Visser M, Stiggelbout AM, van Hilten JJ. Evaluation of the Hospital Anxiety and Depression Scale in patients with Parkinson's Disease. Clin Neuropharmacol 2002;25: 318-24.
29. Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson's disease. Neurology 2004;62:2171-5.
30. Commonwealth of Australia. Guidelines for the pharmaceutical industry of preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis. Canberra (ACT), Department of Health, Housing and Community Services; 1990.
31. SOIKOS Database for Spanish Health Costs, 2004. SOIKOS, S.L. Barcelona (Spain).
32. Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM. Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003; 18:267-74.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistic Soc Series B1995;57:289-300.
34. Development Core Team. A language and environment for statistical computing. Foundation for Statistical Computing, Vienna, Austria (2004). URL http://www.R-project.org.
35. Stata Corp. Stata Statistical Software: Release 8.0. College Station, TX: Stata Corporation, 2003.
36. Spottke A, Reuter M, Machat O, Bornschein B, Campenhausen SV, Berger K, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005;23:817-36.
37. Martínez-Martín P, Lens C, Franch O, Pondal M, Rojo A, García Urra D. Costs of Parkinson's disease in Spain. A pilot study in outpatients. Mov Disord 1998;13:62.
38. Hagell R, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002;17:1213-20.
39. Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl 1):1-27.
40. Leibson CL, Hall Long K, Maraganore DM, Coger JH, Ransom JE, O'Brien PC, et al. Direct medical costs associated with Parkinson's disease. A population-based study. Mov Disord 2006;21: 1864-71.
41. Grandas F, Kulisevsky J. Treatment of Parkinson's disease in Spain. Mov Disord 2003;18:87-9.
42. Muller T, Dodel R, Fritze J. Cost and quality aspects in the treatment of Parkinson's disease. Z Arztl Fortbild Qualitatssich 2006; 100:291-5.
43. Lopiano L, Rizzone M, Bergamasco B, Tavella A, Torre E, Perozzo P, et al. Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes. J Neurol Sci 2002;195:167-70.
44. Singer E. Social costs of Parkinson's disease. J Chronic Dis 1973; 26:243-54.
45. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844-9.
46. Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord 2006;21:362-72.